This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.

Inclusion Criteria:

• Able to take care of self. Out of bed less than 50% of the day
• Absolute neutrophil count >=1,500
• Platelet count >=100,000
• Total bilirubin count <=1.5 times the upper limit of normal

Exclusion Criteria:

• Prior epidermal growth factor receptor antibody
• Prior treatment with Erbitux
• Other cancers